Personalis, Inc. (NASDAQ:PSNL – Get Rating) CFO Aaron Tachibana sold 3,474 shares of the firm’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $3.48, for a total value of $12,089.52. Following the completion of the sale, the chief financial officer now owns 223,669 shares in the company, valued at $778,368.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Personalis Trading Down 4.0 %
NASDAQ:PSNL traded down $0.13 during mid-day trading on Thursday, reaching $3.08. 403,254 shares of the stock were exchanged, compared to its average volume of 522,703. The business has a fifty day moving average price of $3.91 and a 200 day moving average price of $5.07. The firm has a market capitalization of $141.43 million, a PE ratio of -1.47 and a beta of 1.64. Personalis, Inc. has a 1-year low of $3.00 and a 1-year high of $21.69.
Personalis (NASDAQ:PSNL – Get Rating) last released its earnings results on Wednesday, August 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. The firm had revenue of $18.24 million for the quarter, compared to analyst estimates of $15.06 million. Personalis had a negative return on equity of 31.55% and a negative net margin of 122.53%. On average, sell-side analysts forecast that Personalis, Inc. will post -2.48 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Personalis
Institutional investors have recently bought and sold shares of the stock. Prelude Capital Management LLC purchased a new position in Personalis in the 2nd quarter worth about $35,000. Amalgamated Bank purchased a new position in Personalis in the 1st quarter worth about $37,000. Laurion Capital Management LP purchased a new position in Personalis in the 2nd quarter worth about $45,000. Quantbot Technologies LP increased its stake in Personalis by 168.3% in the 1st quarter. Quantbot Technologies LP now owns 9,293 shares of the company’s stock worth $76,000 after purchasing an additional 5,829 shares in the last quarter. Finally, Harvest Management LLC purchased a new position in Personalis in the 1st quarter worth about $82,000. Hedge funds and other institutional investors own 62.19% of the company’s stock.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.
- Get a free copy of the StockNews.com research report on Personalis (PSNL)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.